23-503

23-503 (HMR code: 23-503) is a clinical trial protocol identifier for a Phase I clinical trial sponsored by Nxera Pharma UK Ltd (formerly Heptares Therapeutics Limited) in the United Kingdom. The trial (ISRCTN70080074) is a randomized, controlled, first-in-human study designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of an undisclosed investigational product in healthy volunteers and patients. In accordance with clinical trial registry guidelines, the sponsor has deferred the publication of the full details of the trial, including the specific identity, target, and mechanism of action of the investigational drug, which are expected to be disclosed within 30 months after the trial's completion.